Please contact us for more information or to learn if you are eligible to participate.
To assess the effects of multiple ION224 doses when administered subcutaneously (SC) for 49 weeks (12 months) on NASH histologic improvement, i.e., proportion of subjects achieving at the End of the Treatment at least a 2-point reduction in NAFLD Activity Score (NAS), with at least 1-point improvement in hepatocellular ballooning or lobular inflammation, and without worsening in fibrosis stage.
Principal Investigator | Fernando Membreno, MD |
Co-PI | Frank Cimino |
Sponsor | Ionis Pharmaceuticals |
Type of Trial | Interventional |